For the first time in seven years, a prostate cancer therapy will be added to the Pharmaceutical Benefits Scheme (PBS). From Monday, men with a high-risk form of the disease that no longer responds to traditional testosterone-lowering therapy - known medically as castration resistant prostate ca . by Madison Scott | NBN News-News, Sport & Weather